

新規薬剤開発・評価研究部 論文(2013年)

【英語論文】

原著論文

1. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Combined treatment with erlotinib and a transforming growth factor- β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. *J Thorac Oncol.* 2013;8(3):259-269.
2. Serizawa M, Takahashi T, Yamamoto N, Koh Y. Genomic aberrations associated with erlotinib resistance in non-small cell lung cancer cells. *Anticancer Res.* 2013;33(12):5223-5233.